Primary Results From OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso-Cel) Administered in the Community Setting as Outpatient or Inpatient Treatment in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
关键词
CAR T-cell therapy, large B-cell lymphoma, outpatient treatment, lisocabtagene maraleucel, phase II
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要